[PDF] from peerproject.euN Wallis, M Dawson, J Curry, K Barber, P Beer… - 2011 - repository.peerproject.eu Page 1. For Peer Review AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders Journal: British Journal of Haematology ... features seen in the myeloproliferativediseases (Jamieson et al, 2006; James et al, ... Related articles
RC Skoda… - Cancer Cell, 2011 - Elsevier ... Activating mutations in JAK2 have been found in the majority of patients with myeloproliferative neoplasms (MPN), which represent clonal hematopoietic stem cell diseases characterized by increased proliferation of the erythroid, megakaryocytic, or myeloid lineages. ... All 2 versions
C Khandanpour, C Kosan, MC Gaudreau… - STEM …, 2011 - Wiley Online Library ... Gfi1; Leukemia; Hematopoietic stem cells; Hoxa9; Apoptosis; Myeloproliferativedisease. Abstract. ... In addition, our finding show that Gfi1 prevents the development of myeloproliferativediseases and provides evidence how Gfi1 deficiency could be linked to myeloid leukemia. ... Related articles - All 3 versions
[HTML] from impactjournals.comM Naramura, S Nadeau, B Mohapatra… - …, 2011 - impactjournals.com ... Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. ... 35. Naramura M, Nandwani N, Gu H, Band V, Band H. Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells. ... Cited by 1 - Related articles - Cached - All 3 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
